Loading
A phase 3 trial testing Bomedemstat in myeloproliferative neoplasms, now recruiting.
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) is a phase 3 interventional study registered as NCT06351631, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study. Planned enrolment is 400 participants (estimated). The study started in 2024-05-23 and primary completion is expected in 2034-12-04. No results have been posted on ClinicalTrials.gov.